Cartesian Therapeutics, Inc. (RNAC)
(Real Time Quote from BATS)
$25.96 USD
+1.36 (5.53%)
Updated May 22, 2024 10:36 AM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Income Statements
Fiscal Year end for Cartesian Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 26 | 111 | 85 | 17 | 7 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 26 | 111 | 85 | 17 | 7 |
Selling & Adminstrative & Depr. & Amort Expenses | 112 | 96 | 90 | 73 | 59 |
Income After Depreciation & Amortization | -86 | 15 | -5 | -57 | -52 |
Non-Operating Income | -149 | 23 | -2 | -11 | -1 |
Interest Expense | 3 | 3 | 3 | 2 | 2 |
Pretax Income | -239 | 35 | -10 | -69 | -55 |
Income Taxes | -19 | -1 | 16 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -220 | 35 | -26 | -69 | -55 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -220 | 35 | -26 | -69 | -55 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -86 | 15 | -3 | -56 | -51 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 1 | 2 |
Income After Depreciation & Amortization | -86 | 15 | -5 | -57 | -52 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 5.17 | 4.86 | 3.81 | 3.37 | 1.52 |
Diluted EPS Before Non-Recurring Items | -10.21 | -2.40 | -6.01 | -18.32 | -36.64 |
Diluted Net EPS (GAAP) | -49.85 | 3.00 | -6.61 | -20.42 | -36.64 |
Fiscal Year end for Cartesian Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 5.84 | 8.27 | 6.55 | 5.25 | 5.94 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 5.84 | 8.27 | 6.55 | 5.25 | 5.94 |
SG&A, R&D, and Dept/Amort Expenses | 19.19 | 44.60 | 19.61 | 23.89 | 24.32 |
Income After SG&A, R&D, and Dept/Amort Expenses | -13.35 | -36.33 | -13.06 | -18.64 | -18.38 |
Non-Operating Income | -43.48 | -160.33 | 5.34 | 8.00 | -2.47 |
Interest Expense | 0.00 | 0.00 | 1.27 | 0.75 | 0.81 |
Pretax Income | -56.82 | -196.66 | -9.00 | -11.39 | -21.66 |
Income Taxes | 0.00 | -19.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -56.82 | -177.66 | -9.00 | -11.39 | -21.66 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -56.82 | -177.66 | -9.00 | -11.39 | -21.66 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 5.41 | 5.17 | NA | 5.11 | 5.11 |
Diluted EPS Before Non-Recurring Items | -1.97 | -2.40 | NA | -2.10 | -3.30 |
Diluted Net EPS (GAAP) | -10.50 | -41.74 | -1.80 | -2.10 | -4.20 |